Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer
Open Access
- 10 November 2020
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 8 (2), e001714
- https://doi.org/10.1136/jitc-2020-001714
Abstract
Background Immunogenic cell death (ICD) is a tumor cell death involving both innate and adaptive immune responses. Given published findings that oxaliplatin, but not irinotecan, drives ICD, we investigated whether single nucleotide polymorphisms (SNPs) in the ICD pathway are associated with the efficacy of oxaliplatin-based chemotherapy in metastatic colorectal cancer (mCRC). Methods Two randomized clinical trials data were analyzed: discovery cohort, FOLFOX/bevacizumab arm (MAVERICC); validation cohort, FOLFOXIRI/bevacizumab arm (TRIBE); and two control cohorts, FOLFIRI/bevacizumab arms (both trials). Genomic DNA extracted from blood samples was genotyped. Ten SNPs in the ICD pathway were tested for associations with clinical outcomes. Results In total, 648 patients were included. In the discovery cohort, three SNPs were significantly associated with clinical outcomes in univariate analysis: CALR rs1010222 with progression-free survival (G/G vs any A, HR=0.61, 95% CI 0.43–0.88), ANXA1 rs1050305 with overall survival (OS) (A/A vs any G, HR=1.87, 95% CI 1.04–3.35), and LRP1 rs1799986 with OS (C/C vs any T, HR=1.69, 95% CI 1.07–2.70). Multivariate analysis confirmed the trend, but statistical significance was not reached. In the validation cohort, ANXA1 rs1050305, and LRP1 rs1799986 were validated to have the significant associations with clinical outcome. No significant associations of these SNPs were observed in the two control cohorts. Treatment-by-SNP interaction test confirmed the predictive values. Conclusions The predictive utility of ICD-related SNPs for the efficacy of oxaliplatin-based chemotherapy was demonstrated, warranting further validation studies to be translated into personalized treatment strategies using conventional cytotoxic agents in mCRC.Funding Information
- Daniel Butler Research Fund
- Victoria and Philip Wilson Research Fund
- Dhont Family Foundation
- National Cancer Institute (P30CA 014089)
- San Pedro Peninsula Cancer Guild
- Gloria Borges WunderGlo Foundation
This publication has 27 references indexed in Scilit:
- Biomarker: Predictive or Prognostic?Journal of Clinical Oncology, 2015
- Primary Tumor Location as a Prognostic Factor in Metastatic Colorectal CancerJNCI Journal of the National Cancer Institute, 2015
- Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal CancerThe New England Journal of Medicine, 2014
- Statistical and Practical Considerations for Clinical Evaluation of Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2013
- Immunogenic Cell Death in Cancer TherapyAnnual Review of Immunology, 2013
- The secret ally: immunostimulation by anticancer drugsNature Reviews Drug Discovery, 2012
- A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell deathThe EMBO Journal, 2012
- Immunogenic death of colon cancer cells treated with oxaliplatinOncogene, 2009
- Use of Archived Specimens in Evaluation of Prognostic and Predictive BiomarkersJNCI Journal of the National Cancer Institute, 2009
- Calreticulin exposure dictates the immunogenicity of cancer cell deathNature Medicine, 2006